EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Optimizing polytherapy management for Dravet syndrome in the United States: A National Expert Consensus

Elaine Wirrell iD, Joseph Sullivan

Epilepsia Open · 2026

DOI: 10.1002/epi4.70286 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia Open, 2026. Verfasst von Elaine Wirrell und 1 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Anticonvulsants. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biocodex.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Dravet syndrome (DS) is a severe, drug‐resistant developmental and epileptic encephalopathy (DEE) that requires polytherapy for adequate seizure control. The need to combine multiple antiseizure medications (ASMs), together with variability in seizure types, safety considerations, and evolving patient needs, makes treatment optimization particularly complex for clinicians. As the United States (US) has one of the largest populations of DS patients and pediatric neurologists/epileptologists worldwide, this study aimed to develop US‐focused consensus guidance to guide clinicians in managing treatment combinations in DS.

Methods

A modified Delphi consensus methodology was applied. 35 statements tailored to the US clinical context were developed, covering six key themes: general treatment principles; strategies to support and empower caregivers; stiripentol (STP) as an add‐on to DS‐specific and nonspecific ASMs; use of fenfluramine (FFA) in STP‐containing regimens; use of cannabidiol (CBD) in STP‐containing regimens; and patient follow‐up during treatment initiation. Statements were submitted for online voting to 52 US clinicians with expertise in DS and experience with all approved DS‐specific ASMs. Agreement was rated using a 9‐point Likert scale, with predefined criteria used to determine strong, good, or absent consensus.

Results

26 experts participated in the voting process. Of the 35 statements evaluated, 23 (66%) reached strong consensus, 6 (17%) reached good consensus, and 6 (17%) did not reach consensus. Strong agreement was observed for general principles of DS management, caregiver involvement, structured follow‐up, and several practical aspects of initiating and managing STP‐ and FFA‐containing regimens. Areas without consensus primarily concerned CBD efficacy expectations, dosing strategies, and pharmacokinetic interactions in complex polytherapy regimens. Significance This US‐focused consensus provides structured guidance to support clinical decision‐making in the management of polytherapy for DS. Plain language summary Dravet syndrome is a rare and severe form of epilepsy that begins in early childhood and causes seizures that are difficult to control and often persist throughout life. Because most patients require treatment with multiple medications, managing Dravet syndrome is complex and must adapt as patients grow and their needs change. This US‐focused consensus brings together published evidence and expert clinical experience to provide practical guidance on the management of polytherapy in Dravet syndrome, supporting clinicians in optimizing patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicAnticonvulsantsHumansUnited StatesDrug Therapy, CombinationDelphi TechniqueDioxolanesFenfluramineCannabidiol

Stichwörter der Autor:innen

Antiseizure medicationsDELPHI studyDravet syndromeStiripentolcombination therapyexpert consensus

Substanzen

AnticonvulsantsstiripentolDioxolanesFenfluramineCannabidiol

Autor:innen und Institutionen

  • Divisions of Child and Adolescent Neurology and Epilepsy, Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • Departments of Neurology and Pediatrics, Benioff Children's Hospital, University of California, san Francisco, San Francisco, California, USA.

ORCID-Profile: Elaine Wirrell

Förderung

  • Biocodex

Zitieren

APA

Wirrell, E., & Sullivan, J. (2026). Optimizing polytherapy management for Dravet syndrome in the United States: A National Expert Consensus. Epilepsia Open. https://doi.org/10.1002/epi4.70286

Vancouver

Wirrell E, Sullivan J. Optimizing polytherapy management for Dravet syndrome in the United States: A National Expert Consensus. Epilepsia Open. 2026. doi:10.1002/epi4.70286

BibTeX
@article{Wirrell2026,
  author = {Wirrell, Elaine and Sullivan, Joseph},
  title = {Optimizing polytherapy management for Dravet syndrome in the United States: A National Expert Consensus},
  journal = {Epilepsia Open},
  year = {2026},
  doi = {10.1002/epi4.70286}
}
Kostenlos starten →